JP2020507349A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507349A5 JP2020507349A5 JP2019565165A JP2019565165A JP2020507349A5 JP 2020507349 A5 JP2020507349 A5 JP 2020507349A5 JP 2019565165 A JP2019565165 A JP 2019565165A JP 2019565165 A JP2019565165 A JP 2019565165A JP 2020507349 A5 JP2020507349 A5 JP 2020507349A5
- Authority
- JP
- Japan
- Prior art keywords
- engineered
- cells
- cell
- expression
- fcrγ chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000000822 natural killer cell Anatomy 0.000 claims 82
- 108090000623 proteins and genes Proteins 0.000 claims 55
- 238000000034 method Methods 0.000 claims 41
- 239000000203 mixture Substances 0.000 claims 25
- 102000004169 proteins and genes Human genes 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 18
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 15
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 15
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000002068 genetic effect Effects 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 11
- 230000011664 signaling Effects 0.000 claims 11
- -1 Cd161 Proteins 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 230000001419 dependent effect Effects 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 claims 7
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims 7
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 claims 7
- 230000001629 suppression Effects 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 5
- 230000019491 signal transduction Effects 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 4
- 102100029198 SLAM family member 7 Human genes 0.000 claims 4
- 108091023040 Transcription factor Proteins 0.000 claims 4
- 102000040945 Transcription factor Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 101100377226 Homo sapiens ZBTB16 gene Proteins 0.000 claims 3
- 101150069255 KLRC1 gene Proteins 0.000 claims 3
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims 3
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 108700003766 Promyelocytic Leukemia Zinc Finger Proteins 0.000 claims 3
- 102100040314 Zinc finger and BTB domain-containing protein 16 Human genes 0.000 claims 3
- 102100037796 Zinc finger protein Helios Human genes 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000007783 downstream signaling Effects 0.000 claims 3
- 108091008042 inhibitory receptors Proteins 0.000 claims 3
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100025221 CD70 antigen Human genes 0.000 claims 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 102100028572 Disabled homolog 2 Human genes 0.000 claims 2
- 101150016325 EPHA3 gene Proteins 0.000 claims 2
- 102100031780 Endonuclease Human genes 0.000 claims 2
- 108010042407 Endonucleases Proteins 0.000 claims 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 2
- 102100037362 Fibronectin Human genes 0.000 claims 2
- 108010067306 Fibronectins Proteins 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102000005698 Frizzled receptors Human genes 0.000 claims 2
- 108010045438 Frizzled receptors Proteins 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 2
- 101000915391 Homo sapiens Disabled homolog 2 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101001027081 Homo sapiens Killer cell immunoglobulin-like receptor 2DL1 Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 claims 2
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 claims 2
- 101100284157 Hypocrea jecorina (strain QM6a) cel61b gene Proteins 0.000 claims 2
- 229940126049 IMC-1 Drugs 0.000 claims 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims 2
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims 2
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims 2
- 102000011782 Keratins Human genes 0.000 claims 2
- 108010076876 Keratins Proteins 0.000 claims 2
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 2
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 108010025832 RANK Ligand Proteins 0.000 claims 2
- 102000014128 RANK Ligand Human genes 0.000 claims 2
- 102100031778 SH2 domain-containing protein 1B Human genes 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 108090000058 Syndecan-1 Proteins 0.000 claims 2
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 claims 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102000013127 Vimentin Human genes 0.000 claims 2
- 108010065472 Vimentin Proteins 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 102000036215 folic acid binding proteins Human genes 0.000 claims 2
- 108091011001 folic acid binding proteins Proteins 0.000 claims 2
- 230000037433 frameshift Effects 0.000 claims 2
- 150000002270 gangliosides Chemical class 0.000 claims 2
- 238000003119 immunoblot Methods 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 108091070501 miRNA Proteins 0.000 claims 2
- 239000002679 microRNA Substances 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 230000001052 transient effect Effects 0.000 claims 2
- 210000005048 vimentin Anatomy 0.000 claims 2
- 102000008682 Argonaute Proteins Human genes 0.000 claims 1
- 108010088141 Argonaute Proteins Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101100107081 Danio rerio zbtb16a gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101000707218 Homo sapiens SH2 domain-containing protein 1B Proteins 0.000 claims 1
- 101000599037 Homo sapiens Zinc finger protein Helios Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 101710097986 SH2 domain-containing protein 1B Proteins 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 239000007798 antifreeze agent Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023060549A JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457098P | 2017-02-09 | 2017-02-09 | |
| US62/457,098 | 2017-02-09 | ||
| US201762484350P | 2017-04-11 | 2017-04-11 | |
| US62/484,350 | 2017-04-11 | ||
| PCT/US2018/017493 WO2018148462A1 (en) | 2017-02-09 | 2018-02-08 | Engineered natural killer (nk) cells and compositions and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060549A Division JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507349A JP2020507349A (ja) | 2020-03-12 |
| JP2020507349A5 true JP2020507349A5 (https=) | 2021-03-18 |
Family
ID=63107061
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565165A Withdrawn JP2020507349A (ja) | 2017-02-09 | 2018-02-08 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
| JP2023060549A Pending JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023060549A Pending JP2023089054A (ja) | 2017-02-09 | 2023-04-04 | 操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11920156B2 (https=) |
| EP (1) | EP3580341A4 (https=) |
| JP (2) | JP2020507349A (https=) |
| CN (1) | CN110546265A (https=) |
| AU (2) | AU2018219895C1 (https=) |
| CA (1) | CA3052473A1 (https=) |
| WO (1) | WO2018148462A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| EP4474391A3 (en) * | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| US11591381B2 (en) | 2020-11-30 | 2023-02-28 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| WO2022144632A1 (en) | 2020-12-30 | 2022-07-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| CN114736859B (zh) * | 2022-06-13 | 2022-08-19 | 广东先康达生物科技有限公司 | 一种脐带血nk细胞的培养液及培养方法 |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| WO2025213127A1 (en) | 2024-04-05 | 2025-10-09 | Indapta Therapeutics, Inc. | Treatment of autoimmune diseases or conditions with natural killer cells |
| WO2025245399A1 (en) | 2024-05-23 | 2025-11-27 | Indapta Therapeutics, Inc. | Method of treating cancer with natural killer cells |
| CN119280423A (zh) * | 2024-10-10 | 2025-01-10 | 中南大学 | 一种联合靶向鼻咽癌治疗的载药体系及其制备方法与应用 |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US20020159979A1 (en) | 1994-06-06 | 2002-10-31 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| FR2735789B1 (fr) | 1995-06-23 | 1997-07-25 | Centre Nat Rech Scient | Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant |
| EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
| US6635472B1 (en) | 1997-08-15 | 2003-10-21 | Rubicon Laboratory, Inc. | Retrovirus and viral vectors |
| CA2304168A1 (en) | 1997-09-19 | 1999-04-01 | The Trustees Of The University Of Pennsylvania | Methods and cell line useful for production of recombinant adeno-associated viruses |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| GB9801930D0 (en) | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| EP1058500A4 (en) | 1998-02-27 | 2002-05-08 | Gen Hospital Corp | The helios gene |
| US6436392B1 (en) | 1998-05-20 | 2002-08-20 | University Of Iowa Research Foundation | Adeno-associated virus vectors |
| US20040063094A1 (en) | 1998-05-20 | 2004-04-01 | Biovex Limited | Mutant herpes simplex viruses and uses thereof |
| US6016891A (en) | 1998-08-10 | 2000-01-25 | Sava; John G. | Tree stand harness system |
| ES2340230T3 (es) | 1998-11-10 | 2010-05-31 | University Of North Carolina At Chapel Hill | Vectores viricos y sus procedimientos de preparacion y administracion. |
| GB9904582D0 (en) | 1999-02-26 | 1999-04-21 | Nycomed Imaging As | Process |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6168991B1 (en) | 1999-06-25 | 2001-01-02 | Lucent Technologies Inc. | DRAM capacitor including Cu plug and Ta barrier and method of forming |
| DE19933288A1 (de) | 1999-07-15 | 2001-01-18 | Medigene Ag | Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung |
| US7241447B1 (en) | 1999-10-07 | 2007-07-10 | University Of Iowa Research Foundation | Adeno-associated virus vectors and uses thereof |
| US6723316B2 (en) | 1999-12-22 | 2004-04-20 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth |
| DE60115600T2 (de) | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
| US6653103B2 (en) | 2001-03-30 | 2003-11-25 | Wisconsin Alumni Research Foundation | Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides |
| EP1385466B1 (en) | 2001-05-11 | 2011-03-09 | Wellstat Biologics Corporation | Oncolytic virus therapy |
| US20030044386A1 (en) | 2001-07-11 | 2003-03-06 | Barber Glen N. | Recombinant VSV for the treatment of tumor cells |
| AU2003258060B2 (en) | 2002-03-27 | 2007-07-12 | Baylor College Of Medicine | Potent oncolytic herpes simplex virus for cancer therapy |
| US20030225260A1 (en) | 2002-04-30 | 2003-12-04 | Snyder Richard O. | Production of recombinant AAV virions |
| NZ537255A (en) | 2002-06-21 | 2009-04-30 | Wellstat Biologics Corp | Administration of therapeutic viruses |
| JP2005537802A (ja) | 2002-09-09 | 2005-12-15 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデーション | ラブドウイルスの組み換え型変異体及びその使用方法 |
| DE602004018284D1 (de) | 2003-03-27 | 2009-01-22 | Ottawa Health Research Inst | Mutante vesicular stomatitis viren und deren verwendungen |
| US7731974B2 (en) | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| EP1644492B1 (en) | 2003-06-18 | 2009-01-07 | Genelux Corporation | Modified recombinant vaccinia viruses, uses thereof |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| WO2005049846A2 (en) | 2003-11-17 | 2005-06-02 | Crusade Laboratories Limited | Mutant herpes simplex virus and use thereof in the treatment of squamous cell cancer |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| WO2005116224A2 (en) | 2004-05-18 | 2005-12-08 | Children's Memorial Hospital | Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system |
| WO2005118854A1 (en) | 2004-06-01 | 2005-12-15 | Centre Hospitalier Regional Et Universitaire De Tours | Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies |
| US7427396B2 (en) | 2004-06-03 | 2008-09-23 | Genzyme Corporation | AAV vectors for gene delivery to the lung |
| US7731952B2 (en) | 2004-06-24 | 2010-06-08 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| DE602005016683D1 (de) | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| JP5525689B2 (ja) | 2004-11-02 | 2014-06-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 過剰増殖性障害を処置するための組成物および方法 |
| WO2006060314A2 (en) | 2004-12-01 | 2006-06-08 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| AU2006252406B2 (en) | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| CN101495126B (zh) | 2005-06-23 | 2016-01-06 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| US7943374B2 (en) | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| EP2426142A3 (en) | 2006-10-16 | 2012-06-13 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| WO2008140621A2 (en) | 2006-12-21 | 2008-11-20 | Mount Sinai School Of Medicine Of New York University | Transgenic oncolytic viruses and uses thereof |
| EP2114420B1 (en) | 2007-02-16 | 2016-01-27 | Virttu Biologics Limited | Herpes simplex viruses and methods of viral replication |
| WO2008133938A2 (en) * | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
| JP5213075B2 (ja) | 2007-06-15 | 2013-06-19 | ジェネラックス・コーポレイション | 腫瘍の画像化および／または処置のための微生物 |
| WO2009011924A1 (en) | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| JP5282040B2 (ja) | 2007-09-28 | 2013-09-04 | オリンパス株式会社 | Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法 |
| US20090136917A1 (en) | 2007-10-25 | 2009-05-28 | Szalay Aladar A | Systems and methods for viral therapy |
| US8313896B2 (en) | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009139921A2 (en) | 2008-05-16 | 2009-11-19 | Genelux Corporation | Microorganisms for preventing and treating neoplasms accompanying cellular therapy |
| EP2307033A4 (en) | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS |
| KR101133185B1 (ko) | 2008-07-29 | 2012-04-06 | 서울대학교병원 | 자연살해세포의 증식방법 |
| US8481297B2 (en) | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| US8877182B2 (en) | 2009-03-26 | 2014-11-04 | Cellprotect Nordic Pharmaceuticals Ab | Expansion of NK cells |
| WO2012061814A1 (en) | 2010-11-05 | 2012-05-10 | Transgenomic, Inc. | Pcr primers and methods for rapid and specific genotyping |
| US10066207B2 (en) * | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| US9902973B2 (en) * | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| AU2015289644A1 (en) * | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| US20170137784A1 (en) | 2015-03-23 | 2017-05-18 | Cellex Corporation | NK Cell Culture Container And NK Cell Culture Method |
| CN107708741A (zh) | 2015-06-12 | 2018-02-16 | 免疫医疗公司 | 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法 |
| EP4043556B1 (en) * | 2015-06-30 | 2024-02-07 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
| ES2970269T3 (es) | 2015-07-29 | 2024-05-27 | Onk Therapeutics Ltd | Linfocitos citolíticos naturales modificados y líneas de linfocitos citolíticos naturales que tienen citotoxicidad aumentada |
| WO2017048809A1 (en) * | 2015-09-14 | 2017-03-23 | Regents Of The University Of Minnesota | Nk cells exhibiting an adaptive phenotype and methods for preparing and for using |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3010236A1 (en) | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| EP3405568A4 (en) | 2016-01-20 | 2019-12-04 | Fate Therapeutics, Inc. | COMPOUNDS AND METHODS FOR IMMUNOCELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES |
| CN109844099B (zh) | 2016-07-25 | 2024-01-02 | 美国政府(由卫生和人类服务部的部长所代表) | 产生经修饰的自然杀伤细胞的方法及使用方法 |
| CN110546265A (zh) | 2017-02-09 | 2019-12-06 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞及其组合物和方法 |
| EP3539552A1 (en) | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| JP6543375B1 (ja) | 2018-03-27 | 2019-07-10 | 株式会社ガイアバイオメディシン | ケモカインレセプターと細胞接着分子を発現するｃｄ３陰性細胞の集団、およびその利用 |
| EP4474391A3 (en) | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
| US12410402B2 (en) | 2018-11-21 | 2025-09-09 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (NK) cell subset and related compositions and methods |
| CN109652379B (zh) | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用 |
| JP7629414B2 (ja) | 2019-06-04 | 2025-02-13 | ンカルタ・インコーポレイテッド | 免疫療法のための操作されたナチュラルキラー細胞と操作されたｔ細胞の組み合わせ |
-
2018
- 2018-02-08 CN CN201880023443.9A patent/CN110546265A/zh active Pending
- 2018-02-08 AU AU2018219895A patent/AU2018219895C1/en active Active
- 2018-02-08 JP JP2019565165A patent/JP2020507349A/ja not_active Withdrawn
- 2018-02-08 US US16/484,813 patent/US11920156B2/en active Active
- 2018-02-08 EP EP18750838.7A patent/EP3580341A4/en active Pending
- 2018-02-08 CA CA3052473A patent/CA3052473A1/en active Pending
- 2018-02-08 WO PCT/US2018/017493 patent/WO2018148462A1/en not_active Ceased
-
2023
- 2023-04-04 JP JP2023060549A patent/JP2023089054A/ja active Pending
-
2024
- 2024-01-31 US US18/429,244 patent/US12564739B2/en active Active
- 2024-10-25 AU AU2024227637A patent/AU2024227637A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020507349A5 (https=) | ||
| JP7300763B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| JP7664913B2 (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| EP3245292B1 (en) | Modified hepatitis post-transcriptional regulatory elements | |
| JP2022515290A (ja) | 改変ｔ細胞、その調製方法および使用 | |
| Campillo-Davo et al. | Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing | |
| JP2021519061A (ja) | 操作された免疫エフェクター細胞およびその使用 | |
| CN114761425A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2021506236A (ja) | 強化された免疫エフェクター細胞およびその使用 | |
| JP2021522839A5 (https=) | ||
| JP2023076572A (ja) | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 | |
| CN112512533A (zh) | 用于治疗癌症的材料与方法 | |
| US20220226379A1 (en) | Dnmt3a knock-out stat5 activated genetically engineered t-cells | |
| JP2019518804A (ja) | 遺伝的に修飾されたｔリンパ球 | |
| JP2023112191A (ja) | 核酸構築物 | |
| EP3703713A1 (en) | Vectors | |
| EP4402177A2 (en) | Compositions of chimeric antigen receptor (car) signaling molecules and uses thereof | |
| WO2022047419A1 (en) | Novel cell lines, methods of producing natural killer cells and uses thereof | |
| Bolsée et al. | Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL | |
| CN115835873A (zh) | 用于产生表达重组受体的供体分批细胞的方法 | |
| US20240366759A1 (en) | Method for preserving developmental potential of immune cells used for adoptive cellular therapies | |
| CN118742571A (zh) | 用于细胞免疫学的组合物和方法 | |
| JP2023554376A (ja) | キメラ抗原受容体（ｃａｒ）スペーサー修飾のｃａｒ ｔ細胞機能の増強 | |
| Dragon et al. | LMP2A‐Targeting CAR‐T Cells Equipped With Inducible IL‐18 to Address EBV‐Associated Malignancies |